title: Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
abstract: Febrile neutropenia (FN) is a common and serious complication among cancer patients undergoing myelosuppressive chemotherapy. FN should be treated as a medical emergency because it can lead to life-threatening complications if appropriate treatment is not initiated immediately. This study provides a critical review on the current management of FN and identifies possible directions to optimize FN management.
authors.affiliation: Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore.|Department of Pharmacy, National Cancer Centre Singapore, Singapore, 169610, Singapore.
authors.forename: Xiao Jun
authors.initials: XJ
authors.lastname: Wang
authors.affiliation: Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore. phaac@nus.edu.sg.|Department of Pharmacy, National Cancer Centre Singapore, Singapore, 169610, Singapore. phaac@nus.edu.sg.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019468:Disease Management; D064420:Drug-Related Side Effects and Adverse Reactions; D064147:Febrile Neutropenia / Q000139:chemically induced / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
keywords: Biomarker; Economic evaluation; Febrile neutropenia; Management; Optimization; Patient-reported outcome